McPhersons (ASX:MCP) - Resigned CEO & Managing Director, Laurie McAllister
Resigned CEO & Managing Director, Laurie McAllister
Source: The CEO Magazine
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Laurie McAllister has resigned as CEO and Managing Director of McPherson’s (MCP), effective December 9
  • Laurie has led the health and wellness company over the past four years and MCP says he leaves the company in a strong position for future growth
  • One of his highlights is the successful acquisition of Global Therapeutics in NSW
  • In the interim, Non-Executive Director Grant Peck will replace Laurie to aid in the transition to a more permanent holder
  • McPherson’s will now begin the steps to appoint a more permanent CEO and Managing Director and will provide further announcements in due course
  • Company shares are down 6.8 per cent and are trading at $1.17

Laurie McAllister has resigned as CEO and Managing Director of McPherson’s (MCP), effective December 9.

Laurie has led the health and wellness company over the past four years and MCP says he leaves the company in a strong position for future growth.

One of his highlights is the successful acquisition of Global Therapeutics in Byron Bay, NSW.

Before joining McPherson’s, Laurie worked at Coca-Cola for 23 years, where he had a stint as the Chief Commercial & Marketing Officer for Japan.

Laurie will remain available for a short period of time to assist McPherson’s executive team if required.

In the interim, Non-Executive Director Grant Peck will replace Laurie, effective December 10. This will provide continuity and aid in the transition to a more permanent holder.

Grant has been a Non-Executive Director since December 2017 and is also a member and Chairman of McPherson’s Audit, Risk Management and Compliance Committee.

McPherson’s will now begin the steps to appoint a more permanent CEO and Managing Director and will provide further announcements in due course.

Company shares are down 6.8 per cent and are trading at $1.17 at 2:10 pm AEDT.

MCP by the numbers
More From The Market Online

Optiscan agreement with Mayo Clinic aims to expedite robotic surgery

Optiscan Imaging is parterning with Mayo Clinic to develop a digital confocal laser endomicroscopic imaging system

NDC BidCo acquires all of Pacific Smiles Group

Pacific Smiles Group (ASX:PSQ) has entered into an agreement with NDC BidCo Pty, to be fully…

Recce breathes better on positive lung infection drug pilot test results

Recce Pharmaceuticals Ltd has revealed positive results from its pilot test on synthetic drug Recce 327,…

What it takes to get a new drug to market in Australia

In this latest version of Thematica from TMO, we're taking a break from mines and battery…